Sales & Marketing Bluesky offers an opportunity pharma should not ignore As X becomes a battleground for increasingly polarised debate, its lesser-known (but strikingly similar) cousin Bluesky is rapidly gaining traction.
Oncology Inside ESMO 2024: Treatments, trials, and top HCPs on social... Discover the latest treatments, clinical trials, and top healthcare professionals sharing insights on social media from the ESMO 2024 conference.
Debates & Insight Sponsored Optimising patient outcomes through physician education Physician education is undergoing a massive change as the volume of advances in therapies and practices increases and the use of digital channels facilitates new forms of scientific exchange.&n
Debates & Insight Sponsored Computer Gaming: The Future of Decision-Making for Life Scie... How can life science brands identify winning strategic decisions when there are so many variables to consider?
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.